Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy

MLA

Anton Vonk-Noordegraaf, et al. “Changes in CMRI Parameters Following a Switch to Riociguat from Phosphodiesterase Type 5 Inhibitors (PDE5i) in Patients with Pulmonary Arterial Hypertension: A REPLACE Substudy.” European Heart Journal, vol. 42, Oct. 2021. EBSCOhost, https://doi.org/10.1093/eurheartj/ehab724.1966.

APA

Anton Vonk-Noordegraaf, Andrew J. Peacock, Dario Vizza, Stephan Rosenkranz, HA Ghofrani, Christian Meier, Raymond L. Benza, Marius M. Hoeper, G. Simonneau, Ekkehard Gruenig, & K Vogtlaender. (2021). Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy. European Heart Journal, 42. https://doi.org/10.1093/eurheartj/ehab724.1966

Chicago

Anton Vonk-Noordegraaf, Andrew J. Peacock, Dario Vizza, Stephan Rosenkranz, HA Ghofrani, Christian Meier, Raymond L. Benza, et al. 2021. “Changes in CMRI Parameters Following a Switch to Riociguat from Phosphodiesterase Type 5 Inhibitors (PDE5i) in Patients with Pulmonary Arterial Hypertension: A REPLACE Substudy.” European Heart Journal 42 (October). doi:10.1093/eurheartj/ehab724.1966.